A limited number of patients with adult T cell leukemia/lymphoma (ATL) who received autologous stem cell transplantation (ASCT) have been reported. We report here a case of fatal systemic Candida krusei infection in a female patient with ATL undergoing ASCT. All of the eight patients (including seven patients in the literature) with ATL who received ASCT developed relapse of ATL or death due to ASCT complication, irrespective of subtype or remission state of ATL, source or selection of SCT or conditioning regimen. At present, ASCT appears to provide little benefit for ATL in contrast to that for other types of aggressive non-Hodgkin's lymphoma.
Adult T cell leukemia/lymphoma (ATL) is a distinct clinicopathological entity, ie peripheral T lymphocytic malignancy caused by human T lymphotropic virus type 1 (HTLV-1). 1, 2 Despite recent progress in combination chemotherapy for non-Hodgkin's lymphoma (NHL), acute and lymphoma types of ATL generally have a very poor prognosis with less than 1 year median survival because of infectious complications due to T cell immunodeficiency, multidrug resistance of ATL cells, large tumor burden with multi-organ failure and/or hypercalcemia. [3] [4] [5] At present, there is no standard therapy for ATL in contrast to CHOP therapy for aggressive NHL. 3, 6 High-dose ablative therapy and autologous stem cell transplantation (ASCT) have been shown to be superior to non-ablative therapy in aggressive NHL as initial and salvage treatment. 7, 8 High-dose therapy and ASCT has been reported in a limited number of patients with ATL, but most of those were in the form of an abstract. [9] [10] [11] [12] [13] [14] We report here a case of fatal systemic Candida krusei (C. krusei) infection in a female patient with ATL undergoing ASCT, and review the reported ATL cases that received this therapy.
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Case report
A 33-year-old Japanese woman was referred to a hospital for cough and fever in March 1992. The patient was diagnosed with Pneumocystis carinii pneumonia. She was successfully treated with co-trimoxazole. A few percent of abnormal lymphocytes including flower cells were detected in the peripheral blood without lymphocytosis in May. There was no evident organ involvement and serum lactate dehydrogenase (LDH) and Ca levels were within normal limits. The diagnosis of smoldering ATL was confirmed by HTLV-1 serology and Southern blotting as described. 15 In September 1992, she was hospitalized with systemic lymphadenopathy. Her WBC count was 11 × 10 9 /l (abnormal lymphocytes 33%) and LDH value was 1375 IU/l (normal range, 250-420 IU/l). She was diagnosed as having acute ATL crisis, and treated with four courses of combination chemotherapy (1.5 mg vincristine, 600 mg cyclophosphamide and 60 mg doxorubicin on day 1; 100 mg ranimustine, a nitrosourea derivative and 40 mg pirarubicin, an anthracycline derivative on day 8; 300 mg etoposide and 500 mg carboplatin on day 15 with intermittent G-CSF). Thereafter, she achieved complete remission of ATL. In February 1993, 2.6 × 10 10 cells were harvested from her bone marrow. On 8 March 1993, she received BMT after conditioning with ␣-interferon 3 × 10 6 units s.c. on days Ϫ7 to Ϫ1, doxorubicin 70 mg i.v. on day Ϫ7, ranimustine 420 mg i.v. on day Ϫ7, etoposide 520 mg i.v. on days Ϫ6 to Ϫ4, cytarabine 5600 mg i.v. on days Ϫ6 to Ϫ4, cyclophosphamide 2200 mg i.v. on days Ϫ3 to Ϫ2. Prophylaxis for infection included co-trimoxazole and fluconazol (FCZ) from September 1992. On day 3 after BMT, she developed high fever, sore throat and diarrhea, which were refractory to a combination of ceftazidime, clindamycin and amphotericin B (AMPH). On day 7, she developed pneumonia and C. krusei was detected in blood, sputum and stool. The candida was resistant to FCZ and showed low sensitivity to AMPH and miconazol (MCZ). Neutrophil counts decreased to 0% on day 2 and did not recover despite G-CSF administration. Combination therapy with AMPH and MCZ was not successful and the patient died of hypoxia on day 14. ATL = adult T cell leukemia/lymphoma; ASCT = autologous stem cell transplantation; ABMT = autologous bone marrow transplantation; APBSCT = autologous peripheral blood stem cell transplantation; CR = complete remission; PR = partial remission; ED = early death; NE = not evaluable; UN = unknown; 4-HO = 4-hydroperoxycyclophosphamide; CD34S = CD34-positive cell selection; AraC = cytarabine; Etp = etoposide; MCNU = ranimustine; CY = cyclophosphamide; ADM = doxorubicin; IFN = interferon; TBI = total body radiation; CBDCA = carboplatin; IFM = ifomide; Bu = busulfan; MIT = mitoxantrone; L-PAM = melphalan. 
Discussion
ATL patients often develop infectious complications even when neutrophil counts are over 1 × 10 9 /l. 3 A low dose of co-trimoxazole and antifungal agent is recommended for use together with anticancer agent chemotherapy. This patient had received oral FCZ since remission-induction chemotherapy. Although C. albicans is still the most common pathogen, other species such as C. krusei and C. lusitaniae are isolated with increasing frequency in cancer patients. 16 C. krusei does not respond to FCZ. It appeared in this case that colonization with C. krusei had occurred in the gastro-intestinal tract before the conditioning regimen and became rapidly progressive thereafter. High-dose conditioning regimens should be carefully administered to ATL patients, with particular consideration of underlying infections.
Including this report, eight cases of ASCT have been reported in ATL patients, all of whom were Japanese (see Table 1 ). [9] [10] [11] [12] [13] [14] Relapse or fatal complications occurred in all patients post transplant, irrespective of subtype or remission state of ATL, source or selection of SCT or conditioning regimen. These results are in contrast to the usefulness of high-dose ablative therapy and ASCT in aggressive NHL as initial and salvage treatment as compared with non-ablative therapy. 7, 8 Possible reasons include multidrug resistance of ATL cells, frequent presence of bone marrow or peripheral blood infiltration, and complications due to T cell immunodeficiency caused by HTLV-1. [3] [4] [5] Seven cases of allogeneic transplantation for ATL have been reported. [17] [18] [19] Both of the patients who received alloBMT during a refractory state of ATL, were unsuccessful. Two of the five patients in remission were successfully treated with alloBMT, although the follow-up duration has not yet been long enough.
Further SCT trials for ATL should investigate various types of SCT, SCT selection, conditioning regimen and induction of graft-versus-ATL effect.
In conclusion, ASCT currently appears to provide little benefit for ATL in contrast to that for other types of aggressive NHL.
